IONS Stock Recent News
IONS LATEST HEADLINES
Ionis Pharmaceuticals said on Tuesday its experimental drug met main goal in a late-stage trial testing it as a treatment for a rare genetic disorder known as familial chylomicronemia syndrome.
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis Pharmaceuticals is a pioneering drug developer with a focus on antisense technology. The company has successfully developed four commercially approved drugs for various diseases. Ionis has a strong pipeline of late-stage candidates, including Eplontersen, Olezarsen, and Donidalorsen, with the potential for significant market opportunities.
CARLSBAD, Calif. , Aug. 30, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023 Citi's 18th Annual BioPharma Conference on Thursday, September 7, 2023 Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events.
Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates.
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of a loss of $0.94 per share. This compares to loss of $0.74 per share a year ago.
Webcast scheduled for Wednesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).